Pembrolizumab

Pembrolizumab is a humanized antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1

Research Areas >> Cancer

[1]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X.

PD-L1 inhibitor 1 | PD1-PDL1 inhibitor 1 | PD-1-IN-1 | Avelumab | Sulfamethizole | BMS-1166 | PD1-IN-2